NCT02575456

A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Jiangsu Province Centers for Disease Control and Prevention · Network
• Sex: All
• Age: 8 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults Aged Between 18 and 50 years in Sierra Leone.

Conditions

• Ebola Disease

Interventions

Type	Name	Description
BIOLOGICAL	Ebola Vaccine
BIOLOGICAL	Placebo	control

Timeline

• Start date: 2015-10-01
• Primary completion: 2016-06-01
• Completion: 2016-07-01
• First posted: 2015-10-14
• Last updated: 2016-09-01

Locations

1 site across 1 country: Sierra Leone